A global Phase 3 clinical trial will test whether lucerastat, an experimental oral treatment, can reduce the buildup of fatty substances in the kidneys of people with Fabry disease. These substances can contribute to kidney damage. The study, called FAB-KLEAR (NCT07778667), aims to enroll 16 men with…

A long-term study found that adults and children with Fabry disease receiving enzyme replacement or chaperone therapy generally maintain stable vision and eye structures over a median of 6.5 years. While the nerve fiber layer in the retina — the light-sensitive tissue at the back of the eye —…

I remember first struggling with strenuous activity as a young boy in middle school. Even before then, I wasn’t as active as my siblings and friends. I avoided activities that required a lot of exertion and accepted that I couldn’t keep up. I remember getting tired quickly and overheating easily.

Kidney involvement in Fabry disease can begin early, even before symptoms or marked loss of kidney function develop, a study has found, highlighting the importance of early diagnosis and monitoring. “These findings support kidney surveillance from childhood onward,” researchers wrote in “Clinical and Laboratory Characteristics of Fabry Disease…

Doctors identified a previously unreported mutation in the GLA gene as the cause of Fabry disease in a woman whose disease mainly affected the heart. The woman received an implantable cardioverter-defibrillator to help protect against dangerous heart rhythm oscillations and later began enzyme replacement therapy with Fabrazyme (agalsidase beta). She…

Careful examination of the heart’s structure raised suspicion of late-onset Fabry disease in a 72-year-old man whose heart abnormalities could not be fully explained by his existing health conditions, a case report describes. The suspected diagnosis emerged only after the man died and an autopsy revealed a severely enlarged…